title: Is schizophrenia a dopamine supersensitivity psychotic reaction?
abstract: Adolf Meyer (1866-1950) did not see schizophrenia as a discrete disorder with a specific etiology but, rather, as a reaction to a wide variety of biopsychosocial factors. He may have been right. Today, we have evidence that gene mutations, brain injury, drug use (cocaine, amphetamine, marijuana, phencyclidine, and steroids), prenatal infection and malnutrition, social isolation and marginalization, can all result in the signs and symptoms of schizophrenia. This clinical picture is generally associated with supersensitivity to dopamine, and activates dopamine neurotransmission that is usually alleviated or blocked by drugs that block dopamine D2 receptors. While the dopamine neural pathway may be a final common route to many of the clinical symptoms, the components of this pathway, such as dopamine release and number of D2 receptors, are approximately normal in schizophrenia patients who are in remission. Postmortem findings, however, reveal more dimers of D1D2 and D2D2 receptors in both human schizophrenia brains and in animal models of schizophrenia. Another finding in animal models is an elevation of high-affinity state D2High receptors, but no radioactive ligand is yet available to selectively label D2High receptors in humans. It is suggested that synaptic dopamine supersensitivity in schizophrenia is an attempt at compensation for the original damage by heightening dopamine neurotransmission pathways (preparing the organism for fight or flight). The dopamine overactivity is experienced subjectively as overstimulation, which accounts for some of the clinical symptoms, with attempts at dampening down the stimulation leading to still other symptoms. Reaction and counter-reaction may explain the symptoms of schizophrenia.
authors.affiliation: Departments of Psychiatry, University of Toronto, 260 Heath St. West, Suite 605, Toronto, Ontario M5P 3L6, Canada.
authors.forename: Mary V
authors.initials: MV
authors.lastname: Seeman
authors.forename: Philip
authors.initials: P
authors.lastname: Seeman
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use; D001921:Brain / Q000378:metabolism / Q000473:pathology; D003072:Cognition Disorders / Q000209:etiology; D004298:Dopamine / Q000378:metabolism*; D049672:History, 19th Century; D049673:History, 20th Century; D006801:Humans; D009474:Neurons / Q000502:physiology; D017448:Receptors, Dopamine D2 / Q000235:genetics / Q000378:metabolism; D012559:Schizophrenia / Q000235:genetics / Q000266:history / Q000378:metabolism* / Q000473:pathology
chemical_list: D014150:Antipsychotic Agents; D017448:Receptors, Dopamine D2; D004298:Dopamine
keywords: D1D2 receptor dimer; D2 receptor; D2D2 receptor dimer; Dopamine release; Mutation; Psychosis; Psychotogens